Publication: Primaquine Pharmacokinetics in Lactating Women and Breastfed Infant Exposures
Issued Date
2018-09-14
Resource Type
ISSN
15376591
10584838
10584838
Other identifier(s)
2-s2.0-85046347661
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Infectious Diseases. Vol.67, No.7 (2018), 1000-1007
Suggested Citation
Mary Ellen Gilder, Warunee Hanpithakphong, Richard M. Hoglund, Joel Tarning, Htun Htun Win, Naw Hilda, Cindy S. Chu, Germana Bancone, Verena I. Carrara, Pratap Singhasivanon, Nicholas J. White, François Nosten, Rose McGready Primaquine Pharmacokinetics in Lactating Women and Breastfed Infant Exposures. Clinical Infectious Diseases. Vol.67, No.7 (2018), 1000-1007. doi:10.1093/cid/ciy235 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46324
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Primaquine Pharmacokinetics in Lactating Women and Breastfed Infant Exposures
Other Contributor(s)
Abstract
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. Background Primaquine is the only drug providing radical cure of Plasmodium vivax malaria. It is not recommended for breastfeeding women as it causes hemolysis in glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals, and breast milk excretion and thus infant exposure are not known. Methods Healthy G6PD-normal breastfeeding women with previous P. vivax infection and their healthy G6PD-normal infants between 28 days and 2 years old were enrolled. Mothers took primaquine 0.5 mg/kg/day for 14 days. Primaquine and carboxyprimaquine concentrations were measured in maternal venous plasma, capillary plasma, and breast milk samples and infant capillary plasma samples taken on days 0, 3, 7, and 13. Results In 20 mother-infant pairs, primaquine concentrations were below measurement thresholds in all but 1 infant capillary plasma sample (that contained primaquine 2.6 ng/mL), and carboxyprimaquine was likewise unmeasurable in the majority of infant samples (maximum value 25.8 ng/mL). The estimated primaquine dose received by infants, based on measured breast milk levels, was 2.98 μg/kg/day (ie, ~0.6% of a hypothetical infant daily dose of 0.5 mg/kg). There was no evidence of drug-related hemolysis in the infants. Maternal levels were comparable to levels in nonlactating patients, and adverse events in mothers were mild. Conclusions The concentrations of primaquine in breast milk are very low and therefore very unlikely to cause adverse effects in the breastfeeding infant. Primaquine should not be withheld from mothers breastfeeding infants or young children. More information is needed in neonates. Clinical Trials Registration NCT01780753.
